<DOC>
	<DOCNO>NCT00891293</DOCNO>
	<brief_summary>This 24-month , open-label extension study follow 8-week double-blind study ( Study LOV111859/OM5 ) 8-week , open-label extension study ( LOV111860/OM5X ) . Study LOV111859/OM5 conduct evaluate whether combination therapy Lovaza ( omega-3-acid ethyl ester ) Antara ( fenofibrate ) would result great reduction serum triglyceride level hypertriglyceridemic subject treatment fenofibrate alone . This second extension 24 month assess continue efficacy adjunctive Lovaza ( omega-3-acid ethyl ester ) [ formerly know Omacor ] therapy hypertriglyceridemic subject treat Antara ( fenofibrate ) lower serum triglyceride ( TG ) level .</brief_summary>
	<brief_title>A Second Open-Label Extension Double-Blind , Parallel , Phase IV Study Assess Efficacy Safety Adjunctive Lovaza® ( Formerly Known Omacor® ) Therapy Hypertriglyceridemic Subjects Treated With Antara™</brief_title>
	<detailed_description>Three study comprise program . Study LOV111859/OM5 ( double-blind study ) follow two open label extension - LOV111860/OM5X ( 1st open label extension - 8 week ) LOV111821/OM5XX ( 2nd open label extension - 24 month ) . Studies LOV111859/OM5 LOV111860/OM5X outline NCT00246636 .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Subjects men woman successfully complete previous openlabel extension study ( LOV111860/OM5X ) meet inclusion exclusion criterion original doubleblind study ( LOV111859/OM5 ) throughout LOV111860/OM5X , renew waiver previously approve protocol deviation . Eligibility entry study base inclusion/exclusion criterion describe doubleblind LOV111859/OM5 protocol . Subjects men woman successfully complete previous openlabel extension study ( LOV111860/OM5X ) meet inclusion exclusion criterion original doubleblind study ( LOV111859/OM5 ) throughout LOV111860/OM5X , renew waiver previously approve protocol deviation . The main eligibility criterion LOV111859/OM5 , 18 to79 year age ( inclusive ) screen fast serum TG level ≥500 mg/dL &lt; 1300 mg/dL BMI ≥ 25 kg/m2 ≤43 kg/m2 . Subjects enrol directly end LOV111860/OM5X LOV111821/OM5XX .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>omega-3-acid ethyl ester</keyword>
	<keyword>Very high triglyceride</keyword>
	<keyword>Lovaza</keyword>
	<keyword>fenofibrate</keyword>
</DOC>